Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX

Recruiting Observational Study
AML - Acute Myeloid Leukemia
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
25 (estimated)
Sponsor
Clinical Hub for Interventional Research (CHOIR) · Government
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML). The main questions it aims to answer are: * Are there new ways to speed up discovery of better treatments for AML patients using AML cells from individual from patients in special mice that can accept human tissue? * Do these mice show trea…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Age 18 years and above 2. Patients with suspicion of AML requiring screening procedures 3. Documented diagnosis of AML by WHO Classification and/or International Consensus Classification. * Regardless of the number and type of prior lines of therapy or eligibility for all…
Contacts

John Pimanda, Professor

+61 000000000

cosmos.jcsmr@anu.edu.au

CONTACT

Mark Polizzotto, Professor

cosmos.jcsmr@anu.edu.au

CONTACT